M&A Corner
H1 Partners with Michael J. Fox Foundation on Parkinson’s Research29 May 2023
H1, a healthcare information platform, has announced that The Michael J. Fox Foundation (MJFF), the world’s largest nonprofit funder of... Continue Reading
|
Celebrity-backed Health Optimization Platform Lifeforce Scores $12M29 May 2023
Lifeforce, a personalized healthcare platform based on a telehealth model, has successfully raised $12 million in a Series A funding... Continue Reading
|
Freenome Acquires Global Immunodiagnostics Developer Oncimmune Ltd29 May 2023
Freenome, a biotech company specializing in early cancer detection, has acquired Oncimmune Ltd, a UK-based immunodiagnostics developer. Oncimmune brings its... Continue Reading
|
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases29 May 2023
Ironwood Pharmaceuticals and VectivBio Holding have entered into a definitive agreement for Ironwood to acquire VectivBio for approximately $1 billion... Continue Reading
|
NeuroFlow, Atlantic Health System Partner to Launch Collaborative Care Model29 May 2023
Pennsylvania-based behavioral health company NeuroFlow has partnered with New Jersey-based Atlantic Health System to implement a collaborative care model for... Continue Reading
|
IDEX Corporation Completes Acquisition of Iridian Spectral Technologies29 May 2023
IDEX Corporation has successfully completed its acquisition of Iridian Spectral Technologies, a leading global company specializing in the design and... Continue Reading
|
Calyxt Announces Stockholder Approval of Merger With Cibus23 May 2023
Calyxt, Inc. has announced the results of its special meeting of stockholders, where all proposals, including the issuance of shares... Continue Reading
|
ArisGlobal Acquires SPORIFY to Expand Regulatory Solutions23 May 2023
ArisGlobal, a life sciences software provider, has acquired SPORIFY, a data harmonization technology solution used by five of the world’s... Continue Reading
|
Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals23 May 2023
Biodexa Pharmaceuticals has signed a non-binding letter of intent to potentially acquire Varian Biopharmaceuticals. The acquisition would enhance Biodexa’s position... Continue Reading
|
Oncomatryx Acquires Tube Pharmaceuticals GmbH to Consolidate its Pioneering Pipeline of ADCs Targeting the Tumor Microenvironment23 May 2023
Oncomatryx has acquired Tube Pharmaceuticals GmbH, the developer of the Cytolysin toxic payload, in a multimillion euro transaction. The acquisition... Continue Reading
|